Vol. 3 No. 8 (2023)
Reimbursement Reviews

Dapagliflozin

decorative image of the issue cover

Published September 8, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses dapagliflozin propanediol monohydrate 10 mg oral tablet.
  • Indication: To reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, and cardiovascular and renal death in adults with chronic kidney disease.